1. TNF Inhibitors

TNF inhibitors and Heart Failure

John J. Cush, Kathryn H. Dao, Catalina Orozco Chronic systemic inflammation yields a notable and proportional risk for myocardial infarction, coronary artery disease, heart failure and cardiovascular (CV) death. The role of tumor necrosis factor (TNF) in the pathogenesis of cardiovascular events and congestive heart failure (CHF) in rheumatoid arthritis (RA) has been well documented (1-4). TNFα...

Spinal Delivery of p38: TNF-alpha Inhibitors

Cécile Viboud, Mark A. Miller, Bryan T. Grenfell, Ottar N. Bjørnstad, Lone Simonsen While air travel contributes to the spread of infl uenza epidemics, the magnitude of impact is not clear compared to other factors—a crucial issue when considering a fl ight ban in the context of pandemic planning. Recent modeling efforts simulating the spread of pandemic infl uenza have concluded that such an i...

Mycobacterial Infections Associated with TNF-α Inhibitors

TNF-α inhibitors: are they carcinogenic?

Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the i...

Pharmacogenetics of TNF inhibitors in rheumatoid arthritis

Etanercept, infliximab and adalimumab have shown clinical benefit in immune-mediated inflammatory diseases; however, the outcome of treatment with these tumour-necrosis factor inhibitors remains insufficient in 40–60% of individuals with rheumatoid arthritis. Moreover, their use is accompanied by adverse events and unintentional immune suppression. Pharmacogenetics has the potential to increase...